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Abstract
Background
Although the success of HIV treatment programs depends on retention and viral suppres-
sion, routine program monitoring of these outcomes may be incomplete. We used data from
the national electronic medical record (EMR) system in Zambia to enumerate a large and
regionally representative cohort of patients on treatment. We traced a random sample with
unknown outcomes (lost to follow-up) to document true care status and HIV RNA levels.
Methods and findings
On 31 July 2015, we selected facilities from 4 provinces in 12 joint strata defined by facility
type and province with probability proportional to size. In each facility, we enumerated adults
with at least 1 clinical encounter after treatment initiation in the previous 24 months. From
this cohort, we identified lost-to-follow-up patients (defined as 90 or more days late for their
last appointment), selected a random sample, and intensively reviewed their records and
traced them via phone calls and in-person visits in the community. In 1 of 4 provinces, we
also collected dried blood spots (DBSs) for plasma HIV RNA testing. We used inverse prob-
ability weights to incorporate sampling outcomes into Aalen–Johansen and Cox proportional
hazards regression to estimate retention and viremia. We used a bias analysis approach to
correct for the known inaccuracy of plasma HIV RNA levels obtained from DBSs. From a
total of 64 facilities with 165,464 adults on ART, we selected 32 facilities with 104,966
patients, of whom 17,602 (17%) were lost to follow-up: Those lost to follow-up had median
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002811 May 31, 2019 1 / 17
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Sikazwe I, Eshun-Wilson I, Sikombe K,
Czaicki N, Somwe P, Mody A, et al. (2019)
Retention and viral suppression in a cohort of HIV
patients on antiretroviral therapy in Zambia:
Regionally representative estimates using a
multistage-sampling-based approach. PLoS Med
16(5): e1002811. https://doi.org/10.1371/journal.
pmed.1002811
Academic Editor: Marie-Louise Newell, University
of Southampton, UNITED KINGDOM
Received: October 4, 2018
Accepted: April 23, 2019
Published: May 31, 2019
Copyright: © 2019 Sikazwe et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its supporting
information files.
Funding: Funding for this study was provided by
the Bill and Melinda Gates Foundation (https://
www.gatesfoundation.org) through grant number
OPP1105071. This research has been facilitated by
the infrastructure and resources provided by the
Johns Hopkins University Center for AIDS
age 36 years, 60% were female (N = 11,241), they had median enrollment CD4 count of 220
cells/μl, and 38% had WHO stage 1 clinical disease (N = 10,690). We traced 2,892 (16%)
and found updated outcomes for 2,163 (75%): 412 (19%) had died, 836 (39%) were alive
and in care at their original clinic, 457 (21%) had transferred to a new clinic, 255 (12%) were
alive and out of care, and 203 (9%) were alive but we were unable to determine care status.
Estimates using data from the EMR only suggested that 42.7% (95% CI 38.0%–47.1%) of
new ART starters and 72.3% (95% CI 71.8%–73.0%) of all ART users were retained at 2
years. After incorporating updated data through tracing, we found that 77.3% (95% CI
70.5%–84.0%) of new initiates and 91.2% (95% CI 90.5%–91.8%) of all ART users were
retained (at original clinic or transferred), indicating that routine program data underesti-
mated retention in care markedly. In Lusaka Province, HIV RNA levels greater than or
equal to 1,000 copies/ml were present in 18.1% (95% CI 14.0%–22.3%) of patients in care,
71.3% (95% CI 58.2%–84.4%) of lost patients, and 24.7% (95% CI 21.0%–29.3%). The
main study limitations were imperfect response rates and the use of self-reported care
status.
Conclusions
In this region of Zambia, routine program data underestimated retention, and the point prev-
alence of unsuppressed HIV RNA was high when lost patients were accounted for. Viremia
was prevalent among patients who unofficially transferred: Sustained engagement remains
a challenge among HIV patients in Zambia, and targeted sampling is an effective strategy to
identify such gaps in the care cascade and monitor programmatic progress.
Author summary
Why was this study done?
• Retention and HIV RNA suppression in HIV treatment programs represent critical
metrics of success, but regionally representative estimates in longitudinal cohorts
remain uncommon.
• Most treatment programs, whether at the national or sub-national level, lack data sys-
tems able to capture patient movement across facilities, which may lead to underesti-
mates of retention.
• HIV RNA suppression levels from routine program monitoring or large-scale cross-sec-
tional studies may miss patients who are lost to follow-up, and therefore those who had
been on treatment, thus underestimating the prevalence of viremia.
• Intensive ascertainment of care status and HIV RNA levels in a numerically small but
randomly selected sample of patients with unknown outcomes can improve our under-
standing of treatment success in real-world program settings.
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What did the researchers do and find?
• We used a multistage sampling approach, in which we first selected facilities and then,
within each facility, selected a random sample of patients who were lost to follow-up—
defined as no contact with a health facility for 90 or more days after last their missed
appointment—for intensive tracing. We also collected dried blood spots in Lusaka Prov-
ince to determine viral load levels in both a sample of lost patients and in-care patients
to estimate the prevalence of viremia in both populations.
• We found that among 165,464 patients on treatment in 64 facilities, 28,111 (17%) were
lost to follow-up. We traced 2,892 of the lost (16%): and found 412 (14%) had died and
1,751 (61%) remained alive. Of those alive, 1,293 (74%) continued to receive treatment,
255 (15%) had stopped, and care status could not be determined in 12%.
• Among all ART patients, using data known to the program before tracing, retention was
67.7% at 2 years; after incorporating findings among the lost patients, retention was
91.2%.
• Among 1,044 participants with a viral load determination (901 in care and 143 who
were lost), viremia was present in 18.1% of those in care, 71.3% of those lost to follow-
up (49.8% of those lost and in care elsewhere and 83.9% of those lost and not in care),
and 24.8% overall.
What do these findings mean?
• We found that patient retention in public ART facilities in Zambia was higher than
apparent in data collected during routine care and monitoring.
• Estimates of viremia that do not account for elevated levels in patients who stop treat-
ment (and are lost to follow-up from cohort studies) or are missing from cross-sectional
studies may overestimate treatment success.
• Viremia among patients lost from one facility who reported engagement in a new facility
was markedly higher than among patients who remained engaged in their original facility:
Even though durable discontinuation from care was relatively infrequent, strategies to con-
sistently engage patients to enhance retention and viral suppression are urgently needed.
Introduction
Assessments of retention and HIV RNA suppression levels after HIV treatment initiation in
routine program settings represent the backbone of data-driven public health efforts to bring
the epidemic under control. As HIV treatment reaches more patients in the era of test-and-
treat, the remaining gaps in the cascade are likely to shift toward retention and adherence as the
key modifiable mediators of success [1–3], which warrant careful assessment. Identifying when
and why patients miss clinical visits, fail to pick up medications, and become viremic can help
programs focus attention on vulnerable periods [4]. In addition, identifying facilities where
retention and viral suppression are lower than at other similar settings can also direct targeting
of additional health systems investments. Indeed, at this phase of the HIV treatment response,
relatively widespread geographical access to treatment and large numbers on treatment already
mean that the next phase in improvement efforts should focus on retention and suppression.
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The importance of accurate measures of retention and viral suppression in routine care
delivery settings, however, brings critical challenges in monitoring into focus. First, many
patients move for social or livelihood reasons. Most programs lack data systems that are inte-
grated in a region to capture movement across facilities. Second, even networked systems will
not link records when patients enroll in new facilities using different names or identifiers,
which is common to avoid being considered uncommitted patients by healthcare workers.
In either case, routinely available data may underestimate retention [5,6]. Similarly, routine
clinic-based viral load monitoring will fail to account for patients who are not coming back to
clinic (i.e., lost to follow-up). In an analysis from the International Epidemiology Databases to
Evaluate AIDS (IeDEA), investigators found that 94% of retained patients were virally sup-
pressed, but this figure dropped to 45% when all lost patients were assumed to be viremic [7].
The Zambia Population-based HIV Impact Assessment (ZAMPHIA) suggested viral suppres-
sion in nearly 90% of people self-reporting ART use; patients lost to follow-up from treatment
programs (and who have not been on treatment for some time) may not be captured in the
denominator, thus potentially overestimating suppression [8].
In this study, we examined retention and viral suppression in a large public health program
across 4 provinces in Zambia, a country with an estimated 1,200,000 adults living with HIV
[8–10]. Building on previous work, we used a sampling-based approach in which we first
selected facilities from 4 provinces (with probability proportional to facility size) and then
intensively tracked a random sample of individuals (inversely proportional to facility size) lost
to follow-up in each of these selected sites. In addition, in 1 of the 4 provinces (Lusaka), we
assessed data on plasma HIV RNA suppression levels among a sample of both in-care and
lost-to-follow-up patients. This approach yielded both a representative estimate of overall
retention and viral suppression in a large region of Zambia and site-level estimates of retention
with enough precision to assess site-to-site variation [11].
Methods
Ethical approval
The protocol and study were approved by the University of Zambia Biomedical Research Eth-
ics Committee (004-06-14), and the institutional review board of the University of Alabama at
Birmingham School of Medicine (F160122006). The full analysis protocol is available in S1
Appendix. The study adhered to good practice guidelines for reporting for cohort studies as
presented in the STROBE statement (S2 Appendix).
Patients and sampling
Our sampling frame consisted of HIV-positive adults 18 years or older who sought HIV care
and treatment services during a 24-month period (1 August 2013 to 31 July 2015) across 64
public health facilities supported with funding from the US President’s Emergency Plan for
AIDS Relief/Centers for Disease Control and Prevention through the Centre for Infectious
Disease Research in Zambia (CIDRZ) in 4 provinces (Western, Lusaka, Eastern, and Southern)
in Zambia. We used a multistage-sampling-based approach to obtain corrected estimates of
retention and viremia [12]. Briefly, we stratified 64 total facilities by province (Eastern, West-
ern, Southern, and Lusaka) and facility type (hospital, urban health center, and rural health
center) and selected facilities within these 12 joint strata with probability proportional to size.
In each selected facility, we enumerated those lost to follow-up (defined as at least 90 days late
for the last visit and not documented to have died or transferred out according to the elec-
tronic medical record [EMR] system), and selected a random sample with a sampling proba-
bility inversely proportional to facility size. In 14 Lusaka facilities selected for this study, we
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obtained dried blood spot (DBS) samples for determining plasma HIV RNA level (viral load)
from both lost patients as well as a systematic sample of patients (defined as every 10th patient)
retained at the facility (S1 Fig). This study predated routine plasma HIV RNA monitoring for
treatment.
Procedures and measurements
Data about patient appointments and visits and sociodemographic and clinical characteristics
were obtained from the EMR system in Zambia (SmartCare) and used to enumerate the lost-
to-follow-up patients. Lost patients were traced between October 2015 and June 2016 by chart
review, phone calls, and in-person visits within the community. We recruited peer health
workers with in-depth knowledge of patient flow within facilities and familiarity with the sur-
rounding communities to carry out tracing. Patients were classified as died if review of EMR,
paper records, or the tracing process found evidence that the patient was deceased. Patients
were classified as alive if spoken to in person or an informant was contacted and reported
knowledge of the patient but no knowledge of death. When information about a patient was
collected from more than 1 informant and was discordant, we used information from closer
relations (e.g., we prioritized information from a spouse over that from a neighbor). When lost
patients were contacted in person, we asked, “Have you seen any doctor, nurse or other profes-
sional health worker (like, pharmacist) for treatment of HIV since your last visit which we
have on file, which was on [X date] at the [original clinic]?” and recorded the date of that sub-
sequent visit if the answer was yes (S3 Appendix). Current care status (i.e., retained in care)
was established only if found through chart review or the patient was contacted in person.
Identities were established by name, nicknames, age, occupation, height, sex, and location of
residence. In Lusaka, we trained tracers to collect DBS, assess sample quality, and transport
DBS cards to the CIDRZ central laboratory. We used the AmpliPrep/COBAS TaqMan HIV-1
Test, version 2.0, to quantify human immunodeficiency virus type 1 (HIV-1) RNA in DBSs.
Viral suppression was defined as less than 1,000 copies/ml.
Analyses
We determined “naïve” estimates of retention using only data available from the facility EMR
for the entire cohort of ART users (which included all patients on ART in the 2-year period
of observation, 1 August 2013 to 31 July 2015) as well as for new ART initiators (who started
ART in this 2-year window). We carried out “revised” estimates that incorporated tracing
outcomes through use of probability weights [13]. Weights were inverse to the probability of
selection at both the patient and facility level, a process that seeks to yield regionally represen-
tative estimates [13,14] (S2 Fig). In the naïve analysis, we estimated the prevalence of 4 care
states during the 2-year observation period using the Aalen–Johansen method [15]: (1) alive
and in care at original clinic, (2) transferred to a new facility (which included only official
transfers), (3) lost to follow-up, or (4) died. In revised estimates, after incorporating findings
from tracing through probability weights, we estimated the prevalence of patients over time in
the following 4 states: (1) alive and in care at the original clinic, (2) transferred to a new clinic
(which included both official and unofficial transfers), (3) alive but out of care, or (4) died. We
used Cox proportional hazards models to identify characteristics associated with being out of
care or deceased in the revised estimates. We examined the proportional hazards assumption
using Schoenfeld residuals [16] (S1 Table), and, in addition to the application of inverse proba-
bility weights to account for sampling, we used inverse probability weights to address missing
predictor data for CD4 count, WHO stage, marital status, and level of education [17]. We used
robust variance estimates to account for clustering by clinic.
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In Lusaka Province, we estimated the prevalence of viremia (viral load� 1,000 copies/ml)
among lost patients alone, then among patients in care at their original clinic, and finally
overall (combining both) by applying sampling weights. We managed bias incurred via the
inaccuracy of DBS-based viral load results by using the documented sensitivity of 80.8% and
specificity of 87.3% (for detecting a viral load of�1,000 copies/ml) as compared to plasma
HIV RNA determination through an outcome misclassification correction approach [18,19]
(S4 Appendix). We used inverse probability weights to account for sampling (S1 Fig) and miss-
ing data in all analyses [17]. Post hoc analyses not predefined in the protocol include analyses
restricted to the contemporary cohort of those initiating ART on or after 1 August 2013, analy-
ses using DBS viral load outcome misclassification correction methods, and an analysis of pre-
dictors of viremia.
Results
As described in previous work, 165,464 patients on ART had at least 1 encounter in the 64
health facilities over the 24 months between 1 August 2013 and 31 July 2015 (Fig 1) [12], of
whom 28,111 (17%) were considered lost to follow-up at the time of sampling. At the 32
selected sites, 104,966 patients made any visit during that time, and 17,602 (17%) were lost
to follow-up. We selected a random sample of 2,892 lost patients (16% of 17,602 lost patients
at 32 selected facilities and 10% of all 28,111 lost in all 64 facilities) for intensive tracing to
ascertain current care status. Of the 2,892 lost and traced, updated information was found
for 2,163 (75%), of whom 1,751 (81%) were alive. Among those found alive, 836 (48%)
were still in care at the original health facility, 457 (26%) had transferred to another facility,
and 255 (15%) were out of care; for 203 (12%) care status remained undetermined (Fig 1).
Patient characteristics among those patients lost, traced, and for whom updated care status
was ascertained were similar to those of the overall population of lost patients in the total
ART cohort (Table 1). Compared to the total ART cohort, new ART initiates with updated
Fig 1. Flowchart depicting sampling and patient outcomes. CIDRZ, Centre for Infectious Disease Research in
Zambia; LTFU, lost to follow-up; PPS, probability proportional to size; SRS, simple random sample.
https://doi.org/10.1371/journal.pmed.1002811.g001
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Table 1. Characteristics of all patients at start of observation on 31 August 2013 (N = 165,464).
Characteristic Total ART cohort Lost Sampled Successfully traced Alive Updated care status
Total number 165,464 28,111 2,892 2,163 1,751 1,548
Age at last visit (years) 39 (33–34) 36 (30–43) 37 (31–44) 37 (31–44) 37 (31–43) 37 (31–44)
Male 59,719 (36) 11,241 (40) 1,187 (41) 909 (42) 703 (40) 615 (40)
Enrollment CD4 count (cells/μl)a 224 (119–357) 220 (115–354) 220 (111–362) 217 (112–352) 231 (124–370) 230 (120–372)
ART initiation CD4 count (cells/μl)b 201 (111–312) 201 (108–318) 200 (103–313) 199 (105–309) 210 (115–319) 208 (114–321)
WHO stage at enrollment
Stage 1 62,116 (38) 10,690 (38) 1,059 (37) 783 (36) 675 (39) 603 (39)
Stage 2 33,288 (20) 5,080 (18) 588 (20) 445 (21) 345 (20) 309 (20)
Stage 3 48,738 (29) 8453 (30) 766 (26) 589 (27) 456 (26) 392 (25)
Stage 4 5,497 (3) 1006 (4) 130 (4) 94 (4) 69 (4) 63 (4)
Unknown 15,825 (10) 2,882 (10) 349 (12) 252 (12) 206 (12) 181 (12)
Province
Eastern 29,701 (18) 3,523 (13) 553 (19) 464 (21) 373 (21) 360 (23)
Lusaka 86,688 (52) 17,754 (63) 1,284 (44) 884 (41) 750 (43) 626 (40)
Southern 24,864 (15) 2,714 (10) 507 (18) 384 (18) 291 (17) 245 (16)
Western 24,211 (15) 4,120 (15) 548 (19) 431 (20) 337 (19) 317 (20)
Year of enrollment
2004–2006 16,198 (10) 1,723 (6) 142 (5) 93 (4) 80 (5) 68 (4)
2007–2009 41,050 (25) 5,538 (20) 570 (20) 435 (20) 354 (20) 329 (21)
2010–2012 53,594 (32) 9,148 (33) 1,015 (35) 758 (35) 639 (36) 573 (37)
2013–2015 54,622 (33) 11,702 (42) 1,165 (40) 877 (41) 678 (39) 578 (37)
Year of ART initiation
2004–2006 15,330 (9) 1,607 (6) 164 (6) 126 (6) 101 (6) 92 (6)
2007–2009 34,144 (21) 4,497 (16) 442 (15) 323 (15) 263 (15) 239 (15)
2010–2012 48,288 (29) 7,726 (27) 854 (30) 652 (30) 557 (32) 502 (32)
2013–2015 67,702 (41) 14,281 (51) 1,432 (50) 1,062 (49) 830 (47) 715 (46)
Duration of ART (days) 1,142 (390–2,139) 535 (98–1,492) 592 (104–1,496) 611 (119–1,508) 673 (159–1,535) 721 (174–1,561)
Disclosure of HIV status to family or friend
No 2,580 (2) 642 (2) 63 (2) 41 (2) 30 (2) 21 (1)
Yes 142,021 (86) 24,027 (85) 2,472 (85) 1,844 (85) 1,489 (85) 1,316 (85)
Unknown 20,863 (13) 3,442 (12) 357 (12) 278 (13) 232 (13) 211 (14)
Education levelc
None 9,660 (6) 1,674 (6) 226 (8) 170 (8) 124 (7) 115 (7)
Lower 48,175 (29) 7,606 (27) 813 (28) 599 (28) 467 (27) 426 (28)
Upper 62,154 (38) 11,542 (41) 1,098 (38) 833 (39) 687 (39) 583 (38)
College 6,398 (4) 1,107 (4) 113 (4) 98 (5) 86 (5) 73 (5)
Unknown 39,077 (24) 6,182 (22) 642 (22) 463 (21) 387 (22) 351 (23)
Marital status
Single 14,965 (9) 3,130 (11) 320 (11) 239 (11) 198 (11) 177 (11)
Married 86,091 (52) 14,422 (51) 1,493 (52) 1,147 (53) 965 (55) 859 (56)
Divorced 16,958 (10) 3,103 (11) 342 (12) 250 (12) 180 (10) 160 (10)
Widowed 16,125 (10) 2,211 (8) 228 (8) 174 (8) 126 (7) 110 (7)
Unknown 31,325 (19) 5,245 (19) 509 (18) 353 (16) 282 (16) 242 (16)
Facility
Rural health center 16,547 (10) 3,163 (11) 633 (22) 536 (25) 434 (25) 403 (26)
Urban health center 92,216 (56) 17,667 (63) 1,476 (51) 1,047 (48) 874 (50) 779 (50)
(Continued)
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care status (N = 483) had a shorter duration of ART (88 days; IQR 1–224), mostly enrolled
in care between 2013 and 2015 (85%; the other 15% enrolled before 2013, but started ART in
the 2-year observation period), and appeared younger in age (median 33 years; IQR 28–40)
(S2 Table).
Among all patients at 2 years, using only EMR data, we found that 67.7% of patients were
retained at the original clinic (95% CI 67.3%–68.3%), 26.5% were lost (95% CI 26.1%–26.8%),
4.6% had officially transferred to a new facility (95% CI 4.5%–4.7%), and 1.2% had died (95%
CI 1.1%–1.2%) (Fig 2; S3 Table)—indicating that 72.3% (95% CI 71.8%–73.0%) were retained
at 2 years (at original clinic or transferred). After incorporating updated tracing outcomes, the
revised 2-year estimates suggested that 76.5% (95% CI 76.0%–76.9%) were retained at the orig-
inal clinic, 14.7% (95% CI 14.5%–14.9%) had officially or unofficially transferred to a new site,
3.9% (95% CI 3.8%–4.1%) were alive and out of care, and 4.9% (95% CI 4.8%–5.0%) had died
(Fig 2; S3 Table), resulting in an updated estimate of 91.2% (95% CI 90.5%–91.8%) retained (at
original clinic or transferred) at 2 years.
Compared to the total ART cohort, new ART initiators were less likely to be retained.
Two-year estimates for this group using only EMR data showed 35.9% were retained (95% CI
31.8%–39.9%), 55.1% were lost, 6.8% transferred (95% CI 6.2%–7.5%), and 2.2% died (95% CI
1.7%–2.8%) (Fig 3; S4 Table), with a total of 42.7% (95% CI 38.1%–47.0%) retained in care (at
original clinic or transferred). Revised Aalen–Johansen estimates incorporating tracing out-
comes through probability weights showed a cumulative proportion of 44.2% who were
Table 1. (Continued)
Characteristic Total ART cohort Lost Sampled Successfully traced Alive Updated care status
Hospital 56,701 (34) 7281 (26) 783 (27) 580 (27) 443 (25) 366 (24)
Values are N (%) or median (IQR).
aMissing for 33,296 (20.1%).
bMissing for 22,374 (13.5%).
cLower = lower/mid-basic schooling; upper = upper-basic/secondary school; college = college/university.
https://doi.org/10.1371/journal.pmed.1002811.t001
Fig 2. Total ART cohort (N = 165,464): Estimated naïve and revised cumulative proportion of patients in care over time. Naïve (a) and revised (b)
estimates. X axis represents days on ART during the cohort observation period (1 August 2013–31 July 2015). “Transfer out” includes official transfers
and—for revised estimates—unofficial transfers to a new clinic ascertained by patient self-report.
https://doi.org/10.1371/journal.pmed.1002811.g002
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retained in care at original clinic (95% CI 40%–48%), 33.1% who had transferred to new clinics
(95% CI 30.7%–35.6%), 9.6% who were out of care (95% CI 8.7%–10.5%), and 13.1% who had
died (95% CI 12.2%–14.1%) (Fig 3; S4 Table), resulting in updated estimates of 77.3% (95% CI
70.5%–84.0%) retained (at the original clinic or transferred) at 2 years.
Revised rates of stopping care varied markedly across health facilities, ranging between 1.3
and 8.8 per 100 person-years (pyrs) in the total cohort (Fig 4a), and 1.8 and 26.3 per 100 pyrs
among the new ART initiators (Fig 4b), and across the 4 provinces, ranging from 4.0 (95% CI
3.5–4.5) per 100 pyrs in Eastern Province to 5.5 (95% CI 4.9–6.2) per 100 pyrs in Lusaka Prov-
ince in the total ART cohort, and from 9.1 (95% CI 7.5–11.0) per 100 pyrs in Eastern Province
to 12.5 (95% CI 10.3–15.2) per 100 pyrs in Lusaka Province among new ART initiates (S3 Fig).
At the individual level, the characteristics most strongly associated with disengagement
were male sex (hazard ratio [HR] 1.82; 95% CI 1.47–2.25; p< 0.001) and years on ART (HR
0.81; 95% CI 0.79–0.84; p< 0.001). In addition, a low CD4 count or being divorced as com-
pared to married at enrollment showed an association with higher disengagement (Table 2).
Fig 3. New ART initiators (N = 49,129): Estimated naïve and revised cumulative proportion of patient in care over time. Naïve (a) and revised (b)
estimates. X axis represents days since ART initiation (all initiated on or after 1 August 2013). “Transfer out” includes official transfers and unofficial
transfers to a new clinic.
https://doi.org/10.1371/journal.pmed.1002811.g003
Fig 4. Naïve and revised facility-level rates of disengagement at the 32 sampled clinics among all ART users and new ART initiates. (a) All ART
users; (b) new ART initiates. pyrs, person-years.
https://doi.org/10.1371/journal.pmed.1002811.g004
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Table 2. Naïve and revised multivariable analyses of factors associated with disengagement (died or alive and out of care).
Baseline characteristic Total ART cohort (N = 165,464) New ART initiators (N = 49,129)
Naïvea Reviseda,b Naïvea Reviseda,b
HR 95% CI p-Value HR 95% CI p-Value HR 95% CI p-Value HR 95% CI p-Value
Sex <0.001 <0.001 <0.001 0.006
Female 1 1 1 1
Male 1.36 1.28–1.45 1.82 1.47–2.25 1.25 1.16–1.34 1.50 1.13–1.99
Age (per 10 years) 0.73 0.71–0.76 <0.001 0.86 0.71–1.02 0.095 0.76 0.73–0.79 <0.001 0.90 0.73–1.11 0.311
Enrollment CD4 count (per 50 cells/μl) <0.001 0.011 <0.001 <0.001
0–100 1 1 1 1
101–200 0.91 0.85–0.96 1.13 0.83–1.59 0.83 0.74–0.92 0.84 0.46–1.53
201–350 0.82 0.77–0.86 0.82 0.61–1.10 0.73 0.68–0.80 0.70 0.45–1.09
351–500 0.81 0.75–0.87 0.57 0.37–0.88 0.73 0.67–0.81 0.33 0.17–0.64
�501 0.87 0.81–0.95 0.68 0.44–1.09 0.76 0.67–0.85 0.53 0.28–1.02
WHO stage <0.001 0.062 <0.001 0.005
1 1 1 1 1
2 1.06 0.98–1.14 1.27 0.92–1.72 1.08 0.95–1.22 1.64 1.07–2.52
3 1.27 1.19–1.35 1.13 0.83–1.52 1.39 1.24–1.56 1.13 0.66–1.94
4 1.53 1.37–1.71 1.83 1.05–3.18 1.86 1.45–2.37 2.04 1.01–4.12
Time on ART prior to study enrollment (per year) 0.81 0.79–0.84 <0.001 0.77 0.68–0.86 <0.001 — — — — — —
Province <0.001 0.515 <0.001 0.581
Lusaka 1 1 1 1
Eastern 0.70 0.66–0.75 1.07 0.75–1.53 0.64 0.47–0.87 0.99 0.51–1.93
Southern 0.51 0.36–0.73 0.73 0.44–1.22 0.48 0.35–0.66 0.65 0.35–1.21
Western 0.96 0.57–1.62 1.05 0.53–2.08 0.87 0.55–1.37 0.73 0.33–1.61
Original facility type 0.382 0.051 0.661 0.629
Urban health center 1 1 1 1
Rural health center 1.06 0.68–1.64 0.77 0.47–1.24 0.97 0.63–1.50 1.13 0.52–2.52
Hospital 0.81 0.56–1.16 0.65 0.46–0.92 0.85 0.60–1.21 0.82 0.49–1.37
Facility size (per 1,000 patients) 0.95 0.90–1.00 0.051 0.93 0.85–1.02 0.123 0.95 0.91–0.99 0.016 0.93 0.83–1.04 0.194
Marital status <0.001 0.007 0.007 0.040
Married 1 1 1 1
Single 1.12 1.03–1.22 1.23 0.79–1.91 1.05 0.94–1.18 1.46 0.98–2.19
Divorced 1.17 1.10–1.25 1.77 1.29–2.45 1.14 1.06–1.24 1.65 1.06–2.57
Widowed 1.12 1.06–1.19 1.12 0.79–1.58 1.08 0.96–1.21 1.58 0.89–2.81
Disclosed HIV status to family or friend 0.086 0.751 0.006 0.463
No 1 1 1 1
Yes 0.88 0.77–1.02 1.12 0.5–2.23 0.78 0.66–0.93 0.74 0.34–1.64
Education levelc 0.069 0.453 0.008 0.621
None 1 1 1 1
Lower 0.85 0.75–0.97 1.02 0.70–1.50 0.85 0.76–0.97 1.19 0.71–2.00
Upper 0.90 0.79–1.02 1.15 0.79–1.68 0.90 0.78–1.03 1.35 0.71–2.56
College 0.93 0.80–1.07 1.53 0.80–2.93 0.83 0.68–1.00 1.84 0.75–4.52
aInverse probability weighting used to account for <20% missing values for education, disclosure, marital status, WHO stage, and CD4 count.
bInverse probability sampling weights further applied to generate revised estimates; robust standard errors for clustering at the facility level.
cLower = lower/mid-basic schooling; upper = upper-basic/secondary school; college = college/university.
HR, hazard ratio.
https://doi.org/10.1371/journal.pmed.1002811.t002
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In the sample of new ART initiates, enrollment CD4 count, WHO stage, and divorce were
associated with disengagement.
Among the 86,688 patients who initiated ART during the study period in Lusaka Province
(where we sought to estimate the prevalence of viremia), 68,934 were retained in care and
17,754 were lost to follow-up. Of a random sample of 798 lost patients who were eligible for
tracing, 400 (50.1%) could not be traced, and for 255 (32.0%), samples could not be obtained
due to either refusals or logistical challenges, resulting in 143 (17.9%) DBS viral load samples.
Characteristics were similar for eligible patients with and without viral load samples (S5
Table). In a systematic sample of retained patients, we obtained 901 DBS viral load samples. In
combination, we analyzed 1,044 DBS viral load results (S1 Fig). After applying inverse proba-
bility weights for sampling and nonresponse, and bias correction for known misclassification
of DBS-based HIV RNA levels (as compared to plasma HIV RNA levels), we found the preva-
lence of viremia among patients retained at their original health facility (using a threshold of
1,000 copies/ml) to be 18.1% (95% CI 14.0%–22.3%). Among the lost patients, which included
both those reporting no care as well as those who unofficially transferred, 71.3% (95% CI
58.2%–84.4%) were viremic. Unofficial transfers and patients out of care had a prevalence of
viremia of 49.8% (95% CI 28.1%–71.4%) and 83.9% (95% CI 67.2%–98.8%), respectively.
Incorporating results among those lost and traced into the underlying cohort using probability
weights yielded an overall prevalence of viremia of 24.7% (95% CI 21.0%–29.3%). In multivari-
able regression using pre-therapy patient characteristics (Table 3), male sex, younger age, and
lower ART initiation CD4 count were associated with viremia. In a model with current care
status, this factor was most strongly associated with viremia. Male sex and time on ART dimin-
ished in significance, but younger age remained strongly associated with viremia in the model
with current care status.
Discussion
We combined targeted supplemental data collection (for updated care status and viral loads)
with large-scale data from a national EMR system to advance our understanding of the public
health response to HIV in Zambia. First, we found that even though a large percentage of
patients missed visits and became lost to follow-up, most patients returned to care and
Table 3. Factors associated with viremia (defined as�1,000 copies/ml) after application of sampling weights and bias correction for sensitivity and specificity of
dried blood spot viral load measurements (N = 1,044).
Predictor No adjustment for current care status Adjusted for current care status
RR 95% CI p-Value RR 95% CI p-Value
Sex 0.029 0.188
Female Ref Ref
Male 1.75 1.06–2.88 1.46 0.83–2.56
Age (per 10 years) 0.58 0.42–0.79 0.001 0.62 0.44–0.89 0.009
ART initiation CD4 count (per 50 cells/μl) 0.87 0.79–0.96 0.006 0.87 0.78–0.97 0.011
Time on ART (per year) 0.91 0.83–1.01 0.065 0.98 0.87–1.09 0.675
Facility size (per 1,000 patients) 1.04 0.95–1.13 0.373 1.09 0.99–1.20 0.095
Care status <0.001
In care, original clinic — — — 1
Unofficial transfer — — — 3.29 1.13–9.54
Out of care — — — 17.44 5.58–54.47
RR, risk ratio.
https://doi.org/10.1371/journal.pmed.1002811.t003
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relatively few patients stopped care altogether. Second, these lapses in retention varied
markedly from 1.8 to 26.3 per 100 pyrs among new ART initiates attending 32 health facilities
across 4 provinces we studied, differences that were incompletely explained by measured
patient and facility characteristics. Third, unsuppressed HIV RNA levels in a population of
treated patients rose substantially when lost-to-follow-up patients were included in estimates.
In this study, viremia rose by 7% on an absolute scale and nearly 40% on a ratio scale when lost
patients were included in the estimates. Patients who were retained within the greater health
system, but not at their original clinics, contributed substantially to the total viremia in the
population: Patient-initiated transfers of care were not well coordinated and safe. These find-
ings suggest that public health HIV treatment services in Zambia, while accomplishing an
enormous task and saving thousands of lives, are of uneven success: Many patients do not
achieve optimal sustained engagement, and they experience viremia and therefore attenuated
clinical benefits of HIV treatment.
When compared to the large-scale cross-sectional ZAMPHIA—which documents a preva-
lence of viral suppression among current HIV ART users of 90% in Zambia [8]—our longitu-
dinal data suggest several additional observations. First, we find the prevalence of viremia in a
population treated within the last 2 years to be 25% when those lost to follow-up are incorpo-
rated into estimates. This is substantially higher than the 10% estimated in ZAMPHIA.
Although this difference could be due in part to measurement error (i.e., limited sensitivity
and specificity) of DBSs, we sought to manage these consequences through bias correction
methods. Another important possibility, however, is that cross-sectional studies do not fully
capture those patients who had been on treatment, but who stopped treatment prior to their
participation in the survey. If these patients do not admit to previous treatment (due to social
desirability bias) or if instruments only ask about current HIV treatment, the denominator
could be artificially small (and viral suppression overestimated) compared to this analysis. In
either case, we found our internal estimates of viral suppression among those in clinic care to
be much higher when lost-to-follow-up patients were included.
The revised estimates of retention and viral suppression do not just change the numerical
estimates, but further illustrate that retention is a multidimensional, complex outcome that
likely requires adaptive, innovative, longitudinal public health practices to improve. On the
one hand, the prevalence of true disengagement (i.e., being alive and out of care) is much
lower in reality than as shown by estimates using EMR data alone. On the other hand, patients
who drop out of care at one site and reenter at another are much more likely to be viremic (at
approximately 50%). Collectively, these 2 observations direct our attention to an important
reality in public health chronic disease management: Patients may move their residence, and
their prioritization of treatment may wax and wane, and these changes represent periods of
vulnerability [20–22]. Innovations to improve the effectiveness of ART programs, such as dif-
ferentiated service delivery, as well as others, must adapt to patients’ lived realities in order to
support durable, long-term engagement in care and viral suppression [23–25].
Ongoing efforts to enhance retention and viral suppression are underway, both in the
environment of this study in Zambia and beyond, but will need continued monitoring, includ-
ing among those inevitably lost to follow-up. Zambia is rapidly scaling up targeted quality
improvement activities in response to these findings, including wider use of differentiated ser-
vice delivery models. Although the improvement of estimates of retention through tracing a
sample of lost patients has been demonstrated in sub-Saharan Africa [5,26,27], this analysis
also highlights the marked heterogeneity across facility-level estimates. The heterogeneity
implies that the intensification or prioritization of retention strategies should be targeted, to
be most efficient, and one should endeavor to understand facility-level and facility–patient
interaction dynamics when implementing support efforts. This targeting of health system
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improvements is aligned with current strategic thinking about targeting resources to those
most in need [5,25,26]. In addition, interventions that facilitate reengagement in care for those
who are found to be disengaged from care are needed. Data suggest that early tracing after a
missed visit (within 1 week) can improve patient contact and return to care [27–29], an inter-
vention that should be considered in this setting, but must occur alongside improvements in
EMR systems and data management to minimize misclassification and wasted tracing efforts.
In our analysis, we observed that the strongest predictors of disengagement were male sex
and advanced HIV disease [5,27]. The recent introduction of the concept of differentiated care
for patients with advanced HIV disease could, over time, have an impact on this higher risk of
disengagement among those who present late to HIV services [24]. Effective approaches to
retaining men in care in sub-Saharan Africa are less clearly defined [30,31]; however, interven-
tions such as home, mobile, or workplace ART distribution and financial incentives that target
men should be conceptualized with consideration of the unique facility characteristics and
community dynamics relevant to the settings where these services may be implemented. Con-
ceptually, those lost to follow-up will have greater prevalence of viremia than those in care. If
this fraction of lost patients is large, then their overall contribution to viremia in a population
is important. These data offer proof of that concept. Among those in care, only 1 in 6 patients
are viremic, whereas over half of those lost to follow-up are viremic. Of note, patients who
silently transferred (i.e., had no official transfer documentation) between facilities also had a
high risk of viremia, highlighting the contribution of treatment gaps during transfer to the
overall infectiousness of this community. Efforts should be made to ensure rapid reengage-
ment in care among those with missed visits by simplifying transfer systems and educating
patients and staff to monitor and document reengagement processes at original or new
facilities.
This study has a number of limitations. Our sample, even though randomly selected, was
affected by imperfect response rates: We did not ascertain outcomes in all those who were
traced. In addition, we ascertained true care status among lost patients by self-report, which
could be influenced by social desirability bias. Self-reported retention status, however, was
highly associated with viral load, lending credibility to this measurement. Furthermore, our
competing risk estimates assumed that unofficial and official transfers remained engaged in
care, an assumption that could lead to an overestimation of retention. Viral load measure-
ments used DBSs, which have known limitations in sensitivity and specificity compared to the
gold standard plasma-based assay; we however used established methods of bias analysis to
correct for DBS inaccuracy.
This study demonstrates how a strategy of sampling and tracing of lost patients can be used
to generate revised estimates of retention and viremia at a population level. For Zambia these
estimates reflected better overall retention than routinely collected program data but also
highlighted significant gaps in care, and marked variation of overall retention at the facility
level among those retained, contributing to high overall viremia in the ART cohort. Substantial
efforts need to be made to tailor services to the needs of patients in order to reduce lapses in
care and maintain long-term viral suppression. Furthermore, understanding facility- and com-
munity-based barriers to retention in care and addressing these barriers remain critical to
attaining the UNAIDS 90-90-90 targets.
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